This invention describes the new 8.beta.-substituted estratrienes of general formula I in which R.sup.2, R.sup.3, R.sup.6, R.sup.6', R.sup.7, R.sup.7', R.sup.9, R.sup.11, R.sup.11', R.sup.12, R.sup.14, R.sup.15, R.sup.15', R.sup.16, R.sup.16', R.sup.17 and R.sup.17' have the meanings that are indicated in the description, and R.sup.8 means a straight-chain or branched-chain, optionally partially or completely halogenated alkyl or alkenyl radical with up to 5 carbon atoms, an ethinyl- or prop-1-inyl radical, as pharmaceutical active ingredients that have in vitro a higher affinity to estrogen receptor preparations of rat prostates than to estrogen receptor preparations of rat uteri and in vivo preferably a preferential action on bone rather than the uterus and/or a pronounced action with respect to stimulation of the expression of 5HT2a-receptors and 5HT2a-transporters, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treatment of estrogen-deficiency-induced diseases and conditions as well as the use of an 8.beta.-substituted estratriene structural part in the total structures of compounds that have a dissociation in favor of their estrogenic action on bones rather than the uterus.